Measuring the knowledge translation and convergence in pharmaceutical innovation by funding-science-technology-innovation linkages analysis

Abstract We propose a backward tracking model for measuring knowledge transfer in the whole translational research spectrum. Using the drugs-patents-papers-grants backward linkages, we try to figure out the funding-science-technology-innovation translational pattern and ponder some policy implications on e.g., which priority areas and knowledge convergence level are more likely to generate new drugs. The drug-patent linkage data was accessed through the USFDA Orange Book, covering a drug's active ingredient, formulation, or methods of use for approved indications. It will take about 10 years from the application of earliest patent to the approval of the new drug. Also such high-value patents in FDA Orange Book tend to cite scientific knowledge published on average 10–15 years ago. The technology linkage of new drugs was relatively stable while the science linkage of technology inventions increased rapidly. Among the scientific papers cited by drug patents, private-institution originated papers are only a quarter of the public. By linking theses scientific papers with funding sources, we found a large majority (90%) are public-funded and only a very small part are private-funded or public-private joint-funded. Our study also indicates the importance of research on such fields as pharmacology, chemistry (including medicinal chemistry, biochemistry, and organic chemistry), molecular biology, neurosciences, and immunology on new drugs innovation. There is no obvious relationship between “basicness” and linkages to the resulting patents’ impact and to drugs innovation. A balanced basic research and applied research maybe essential for fostering drug innovation because it is a complete chain translating from basic discovery to clinical evidence then to clinical practice. In order to achieve successful pharmaceutical innovation, rather than focusing on only technology, convergence with science at moderate levels (maybe 1/3) is suggested.

[1]  E. Dorsey,et al.  The anatomy of medical research: US and international comparisons. , 2015, JAMA.

[2]  Philip Shapira,et al.  Funding acknowledgement analysis: an enhanced tool to investigate research sponsorship impacts: the case of nanotechnology , 2011, Scientometrics.

[3]  A. Stevens,et al.  The role of public-sector research in the discovery of drugs and vaccines. , 2011, The New England journal of medicine.

[4]  Arturo Casadevall,et al.  Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research , 2015, Proceedings of the National Academy of Sciences.

[5]  Chun-Chieh Wang,et al.  Measuring science-based science linkage and non-science-based linkage of patents through non-patent references , 2015, J. Informetrics.

[6]  Gunno Park,et al.  The impact of convergence between science and technology on innovation , 2018 .

[7]  Guo Zhang,et al.  Patent citation analysis: Calculating science linkage based on citing motivation , 2014, J. Assoc. Inf. Sci. Technol..

[8]  John P A Ioannidis,et al.  Translation of highly promising basic science research into clinical applications. , 2003, The American journal of medicine.

[9]  Shih-Chieh Fang,et al.  Tracking R&D behavior: bibliometric analysis of drug patents in the Orange Book , 2011, Scientometrics.

[10]  Li Tang,et al.  Funding acknowledgment analysis: Queries and caveats , 2016, J. Assoc. Inf. Sci. Technol..

[11]  Xiaoli Tang,et al.  The performance of China’s biomedical innovation: a scientometric analysis , 2016, Science China Life Sciences.

[12]  Corinne Alberti,et al.  Using Bibliometrics to Measure the Impact of Cancer Research on Health Service and Patient Care: Selecting and Testing Four Indicators , 2015, ISSI.

[13]  Christian Sternitzke,et al.  Knowledge sources, patent protection, and commercialization of pharmaceutical innovations☆ , 2010 .

[14]  John P A Ioannidis,et al.  Life Cycle of Translational Research for Medical Interventions , 2008, Science.

[15]  Benjamin F. Jones,et al.  The dual frontier: Patented inventions and prior scientific advance , 2017, Science.

[16]  Henk F. Moed,et al.  An exploration of the science base of recent technology , 1990 .

[17]  Bart Van Looy,et al.  Sources of inspiration? Making sense of scientific references in patents , 2014, Scientometrics.

[18]  Yali Friedman Where Are Drugs Invented, and Why Does It Matter? , 2017, ACS medicinal chemistry letters.

[19]  David S. Jones,et al.  Detection and characterization of translational research in cancer and cardiovascular medicine , 2011, Journal of Translational Medicine.

[20]  Yali Friedman,et al.  Location of pharmaceutical innovation: 2000–2009 , 2010, Nature Reviews Drug Discovery.

[21]  Francis Narin,et al.  Is technology becoming science? , 1985, Scientometrics.

[22]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[23]  Uwe Dulleck,et al.  Mapping the global influence of published research on industry and innovation , 2018, Nature Biotechnology.

[24]  Jonathan Grant,et al.  Basic research and health: a reassessment of the scientific basis for the support of biomedical science , 2003 .

[25]  L. McNamee,et al.  Contribution of NIH funding to new drug approvals 2010–2016 , 2018, Proceedings of the National Academy of Sciences.

[26]  Mari Jibu,et al.  Mapping of scientific patenting: toward the development of ‘J-GLOBAL foresight’ , 2014, Technol. Anal. Strateg. Manag..

[27]  Wolfgang Glänzel,et al.  Patents cited in the scientific literature: An exploratory study of 'reverse' citation relations , 2004, Scientometrics.

[28]  Antonio Capaldo,et al.  Knowledge Maturity and the Scientific Value of Innovations , 2017 .

[29]  G. Lewison,et al.  Mapping the emergence and development of translational cancer research. , 2006, European journal of cancer.

[30]  Kevin W. Boyack,et al.  Classification of individual articles from all of science by research level , 2014, J. Informetrics.

[31]  A. Hyman,et al.  Priority of discovery in the life sciences , 2016, eLife.

[32]  Reinhilde Veugelers,et al.  Basic science as a prescription for breakthrough inventions in the pharmaceutical industry , 2013 .

[33]  Li Tang,et al.  Missing author address information in Web of Science-An explorative study , 2018, J. Informetrics.

[34]  Grant Lewison,et al.  The classification of biomedical journals by research level , 2004, Scientometrics.

[35]  G. Weber Identifying translational science within the triangle of biomedicine , 2013, Journal of Translational Medicine.

[36]  G. Duysters,et al.  The technological origins of radical inventions , 2010 .

[37]  Ulrich Dirnagl,et al.  Changing the Mindset in Life Sciences Toward Translation: A Consensus , 2014, Science Translational Medicine.

[38]  Mark P. Carpenter,et al.  Linkage Between Basic Research Literature and Patents , 1980 .

[39]  Gabriel Pinski,et al.  Structure of the Biomedical Literature , 1976, J. Am. Soc. Inf. Sci..

[40]  Michel Goldman,et al.  Measuring the value of public–private partnerships in the pharmaceutical sciences , 2012, Nature Reviews Drug Discovery.

[41]  Robert Cottrell,et al.  Evaluating “payback” on biomedical research from papers cited in clinical guidelines: applied bibliometric study , 2000, BMJ : British Medical Journal.

[42]  Danielle Li,et al.  The applied value of public investments in biomedical research , 2017, Science.

[43]  David L. Deeds,et al.  An Analysis of the Critical Role of Public Science in Innovation: The Case of Biotechnology , 2000 .

[44]  Harvey Brooks,et al.  The relationship between science and technology , 1994 .

[45]  M. Trajtenberg,et al.  University Versus Corporate Patents: A Window On The Basicness Of Invention , 1997 .

[46]  H. Grupp Spillover effects and the science base of innovations reconsidered: an empirical approach , 1996 .

[47]  Thomas Scherngell,et al.  Is the United States Still Dominant in the Global Pharmaceutical Innovation Network? , 2013, PloS one.

[48]  R Klavans,et al.  Accurately identifying topics using text: Mapping PubMed , 2018 .

[49]  Marcus M Reidenberg,et al.  U.S. basic research: delayed drug development. , 2012, Science.

[50]  Richard Jefferson Comment: Turning science into social outcomes , 2017, Nature.